An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2003

O'Farrell Anne-Marie, Foran James M, Fiedler Walter, Serve Hubert, Paquette Ron L, Cooper Maureen A, Yuen Helene A, Louie Sharianne G, Kim Heidi, Nicholas Susan, Heinrich Michael C, Berdel Wolfgang E, Bello Carlo, Jacobs Mark, Scigalla Paul, Manning William C, Kelsey Stephen, Cherrington Julie M

Abstract excerpt

PURPOSE: Obtaining direct and rapid proof of molecular activity in early clinical trials is critical for optimal clinical development of novel targeted therapies. SU11248 is an oral multitargeted kinase inhibitor with selectivity for fms-related tyrosine kinase 3/Flk2 (FLT3), platelet-derived gro...

Topics

Administration, Oral
Adult
Aged
Blast Crisis
Enzyme Inhibitors
Female
Genotype
Humans
Indoles
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Male

Metabolic Clearance Rate

Middle Aged

Mitogen-Activated Protein Kinases

Phosphorylation

Proto-Oncogene Proteins

Pyrroles

Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 14654525

Genes

FLT3
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-14654525-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.